Friday, 23 Oct 2026

Empowering Chinese Pharma’s Global Expansion

Contact US
Insight,  China's Pharmaceutical Industry
  • Home
  • About US
  • Policy Hub
  • Categories
    • Drug
    • Company
    • Deals
    • Policy / Regulatory
    • Medical Device
    • R&D
    • Legal / IP
    • Digital
  • Privacy Policy
  • Contact US
My News
  • Cancer
  • Clinical trial approval / initiation
  • Product approvals
  • Clinical trial results
  • Finance
  • ADC / XDC
  • Finanical Reports
  • Biotech
  • Market approval filings
  • PD-1/L1
Insight,  China's Pharmaceutical IndustryInsight,  China's Pharmaceutical Industry
  • Read History
Search
  • Pages
    • Home
    • Blog Index
    • POLICY HUB
    • Contact Us
  • Personalized
    • Read History
  • Categories
    • Company
    • Drug
    • Policy / Regulatory
    • Medical Device
    • R&D
    • Digital
    • Legal / IP
    • Deals
Have an existing account? Sign In
Follow US
HutchMed Completes Patient Enrollment for Orpathys in Gastric Cancer Trial
CompanyDrug

HutchMed Completes Patient Enrollment for Orpathys in Gastric Cancer Trial

April 22, 2025
Akeso's Ebdarokimab Receives NMPA Approval for Moderate to Severe Plaque Psoriasis
CompanyDrug

Akeso’s Ebdarokimab Receives NMPA Approval for Moderate to Severe Plaque Psoriasis

April 21, 2025
Shanghai Healthcare Administration Pushes for 11th Round of VBP
Policy / Regulatory

Shanghai Healthcare Administration Pushes for 11th Round of VBP

April 21, 2025
Vivolight's Multimodal Coronary OCT System Gains FDA Clearance
CompanyMedical Device

Vivolight’s Multimodal Coronary OCT System Gains FDA Clearance

April 21, 2025
Belief BioMed Gains NMPA Clinical Trial Approval for DMD Gene Therapy BBM-D101
CompanyDrug

Belief BioMed Gains NMPA Clinical Trial Approval for DMD Gene Therapy BBM-D101

April 21, 2025
Sanofi's Dupixent Approved by FDA for Chronic Spontaneous Urticaria
CompanyDrug

Sanofi’s Dupixent Approved by FDA for Chronic Spontaneous Urticaria

April 21, 2025
Biogen's High-Dose Spinraza Regimen Accepted for CDE Review in China
CompanyDrug

Biogen’s High-Dose Spinraza Regimen Accepted for CDE Review in China

April 21, 2025
Sichuan Biokin Gains NMPA Approval for Phase II Trials of BL-B01D1 in Combination Therapies
CompanyDrug

Sichuan Biokin Gains NMPA Approval for Phase II Trials of BL-B01D1 in Combination Therapies

April 21, 2025
Walvax Biotech Gains NMPA Clinical Clearance for 20-Valent Pneumococcal Vaccine
CompanyDrug

Walvax Biotech Gains NMPA Clinical Clearance for 20-Valent Pneumococcal Vaccine

April 21, 2025
Asieris Pharmaceuticals Reports Strong 2024 Financial Results for Urogenital Cancer Drugs
Company

Asieris Pharmaceuticals Reports Strong 2024 Financial Results for Urogenital Cancer Drugs

April 21, 2025
Shandong Lukang Plans Private Placement to Raise RMB1.2 Billion for Drug Development
CompanyDeals

Shandong Lukang Plans Private Placement to Raise RMB1.2 Billion for Drug Development

April 21, 2025
Dizal's Golidocitinib Receives CSCO Class 1 Recommendation for PTCL Treatment
CompanyDrug

Dizal’s Golidocitinib Receives CSCO Class 1 Recommendation for PTCL Treatment

April 21, 2025
1 2 … 185 186 187 188 189 … 289 290
Insight,  China's Pharmaceutical Industry

Information You Can Trust: Stay instantly connected with breaking stories and live updates. From politics and technology to entertainment and beyond, we provide real-time coverage you can rely on, making us your dependable source for 24/7 news.

Youtube Medium Rss

About Company

  • Contact Us
  • Advertise with US
  • Complaint
  • Our Team
  • Our Values
  • Privacy Policy
Subscribe Now for Real-time Updates on the Latest Stories!

© 2026 Fineline Information & Technology. Independent intelligence on China’s pharmaceutical industry.  All Rights Reserved.

Fineline Information & Technology
Welcome to Fineline Cube!
Username or Email Address
Password

Lost your password?

Not a member? Sign Up